Feature | August 13, 2012

Support Services Critical as Providers Migrate to Hybrid OR, Says Recent KLAS Study

August 13, 2012 — Providers are increasingly focused on using interventional labs in a hybrid operating room (OR) environment, but better support and training are needed to ensure success in this evolution of technology, suggests some of the findings in a recent KLAS study, “Interventional X-ray 2012: A Continuing Evolution.”

The research indicates that providers are specifically looking for vendors' training quality and readiness for hybrid OR suites when selecting interventional X-ray systems. Healthcare providers across the United States expressed their opinions regarding four specific vendors in the market. For the third year in a row, Toshiba earned the top score for overall satisfaction, followed by Phillips, GE and Siemens. Providers highlighted Toshiba's field support, proactive service and account management. However, Toshiba has only two of their participating customers currently using the Infinix-i as a hybrid OR.

Conversely, with 13 customers using their equipment in a hybrid OR, Siemens has the greatest market penetration in this area. Although providers rated Siemens fourth place overall, Kirk Ising, report author and strategic operations director at KLAS, says that may come with the territory. The reason is that hybrid OR requires a much more complex process to set up, and training is difficult to coordinate and execute effectively.

"Currently, providers who are using a hybrid OR are early adopters," Ising said. "And although Siemens has been first to the table with the technology piece, they will need to improve their contracting, training and implementation processes to better meet providers' expectations."

While Phillips scored higher than Siemens overall, they only have two customers using the FD20 in a hybrid OR. When it comes to implementations, Philips customers report that communication is excellent. However, communication seems to fall off post-implementation, which appears to disappoint hands-on managers.

Provider satisfaction with GE's Innova 3100 has steadily improved in the past five years, giving GE third place in this study. Better service and support have helped GE make their customers more satisfied. The Innova 3100 is not being used in any hybrid OR settings because it is a floor-mounted unit. In order to tap the hybrid OR market, GE released the Discovery IGS 730, which is meant for hybrid OR use, but there are not enough live sites to measure it for the 2012 study.

For more information: www.KLASresearch.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init